Literature DB >> 12384915

CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis.

Norikuni Kawanaka1, Masahiro Yamamura, Tetsushi Aita, Yoshitaka Morita, Akira Okamoto, Masanori Kawashima, Mitsuhiro Iwahashi, Akiko Ueno, Yasukazu Ohmoto, Hirofumi Makino.   

Abstract

OBJECTIVE: CD14+,CD16+ monocytes, identified as a minor population of monocytes in human peripheral blood (PB), have been implicated in several inflammatory diseases. We undertook this study to investigate the relevance of this phenotype to joint inflammation in rheumatoid arthritis (RA).
METHODS: The expression of CD14, CD16, CC chemokine receptor 1 (CCR1), CCR5, and intercellular adhesion molecule 1 (ICAM-1) on monocytes was measured by flow cytometric analysis. Concentrations of the cytokines known to induce CD16 (including transforming growth factor beta1 [TGFbeta1], macrophage colony-stimulating factor [M-CSF], and interleukin-10 [IL-10]) and concentrations of the soluble form of CD14 (sCD14) in plasma and synovial fluid (SF) samples were measured by enzyme-linked immunosorbent assay. The induction of CD16 on RA blood monocytes cultured for 18 hours with 1 or with all 3 cytokines was determined.
RESULTS: The mean +/- SD frequency of CD14+,CD16+ blood monocytes was significantly increased in RA patients (11.7 +/- 5.6%; n = 105) compared with healthy controls (9.5 +/- 2.2%; n = 15) (P < 0.01), and the patient group with an increased frequency of CD16+ monocytes (> or =13.9%) had active disease, as defined by increased counts of tender and swollen joints, levels of acute-phase reactants, and titers of rheumatoid factor. The response to drug therapy correlated with changes in the frequency of this phenotype. The expression of CD16 on SF monocytes from RA patients was markedly elevated compared with the expression on PB monocytes. CD16 expression on RA blood monocytes was augmented in vitro by IL-10, M-CSF, and TGFbeta1. Plasma concentrations of these cytokines and of sCD14 were significantly higher in RA patients with high CD16+ monocyte frequencies than in those with low CD16+ monocyte frequencies or in healthy controls. CD14+,CD16+ monocytes expressed higher levels of CCR1, CCR5, and ICAM-1 than did regular CD14++,CD16- monocytes, particularly in active RA.
CONCLUSION: These results indicate that the maturation of blood monocytes into tissue-infiltrative CD16+ cells before entry into the joint, induced by cytokine spillover from the inflamed joint, may contribute to the persistent joint inflammation of RA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384915     DOI: 10.1002/art.10545

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  124 in total

1.  Investigating the role of proinflammatory CD16+ monocytes in the pathogenesis of inflammatory bowel disease.

Authors:  S Koch; T Kucharzik; J Heidemann; A Nusrat; A Luegering
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  Surface APRIL Is Elevated on Myeloid Cells and Is Associated with Disease Activity in Patients with Rheumatoid Arthritis.

Authors:  Abby Jones Weldon; Ioana Moldovan; Marven G Cabling; Elvin A Hernandez; Sheri Hsu; Jennifer Gonzalez; Andrea Parra; Abigail Benitez; Nasim Daoud; Keith Colburn; Kimberly J Payne
Journal:  J Rheumatol       Date:  2015-03-01       Impact factor: 4.666

Review 3.  Nonclassical patrolling monocyte function in the vasculature.

Authors:  Graham Thomas; Robert Tacke; Catherine C Hedrick; Richard N Hanna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-02       Impact factor: 8.311

4.  Selective expansion of CD16highCCR2- subpopulation of circulating monocytes with preferential production of haem oxygenase (HO)-1 in response to acute inflammation.

Authors:  K Mizuno; T Toma; H Tsukiji; H Okamoto; H Yamazaki; K Ohta; K Ohta; Y Kasahara; S Koizumi; A Yachie
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

5.  Longitudinal analysis of activation markers on monocyte subsets during the development of simian immunodeficiency virus encephalitis.

Authors:  Stephanie J Bissel; Guoji Wang; Anita M Trichel; Michael Murphey-Corb; Clayton A Wiley
Journal:  J Neuroimmunol       Date:  2006-06-21       Impact factor: 3.478

6.  CD14++CD16+ Monocytes Are Enriched by Glucocorticoid Treatment and Are Functionally Attenuated in Driving Effector T Cell Responses.

Authors:  Baoying Liu; Ashwin Dhanda; Sima Hirani; Emily L Williams; H Nida Sen; Fernando Martinez Estrada; Diamond Ling; Ian Thompson; Megan Casady; Zhiyu Li; Han Si; William Tucker; Lai Wei; Shayma Jawad; Amol Sura; Jennifer Dailey; Susan Hannes; Ping Chen; Jason L Chien; Siamon Gordon; Richard W J Lee; Robert B Nussenblatt
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

7.  Inflammatory markers CD11b, CD16, CD66b, CD68, myeloperoxidase and neutrophil elastase in eccentric exercised human skeletal muscles.

Authors:  Gøran Paulsen; Ingrid Egner; Truls Raastad; Finn Reinholt; Simen Owe; Fredrik Lauritzen; Sverre-Henning Brorson; Satu Koskinen
Journal:  Histochem Cell Biol       Date:  2012-12-07       Impact factor: 4.304

8.  Squamous carcinoma cells influence monocyte phenotype and suppress lipopolysaccharide-induced TNF-alpha in monocytes.

Authors:  Aroonwan Lam-ubol; Dustin Hopkin; Elena M Letuchy; Zoya B Kurago
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

9.  Defective cholesterol metabolism in haematopoietic stem cells promotes monocyte-driven atherosclerosis in rheumatoid arthritis.

Authors:  Dragana Dragoljevic; Michael J Kraakman; Prabhakara R Nagareddy; Devi Ngo; Waled Shihata; Helene L Kammoun; Alexandra Whillas; Man Kit Sam Lee; Annas Al-Sharea; Gerard Pernes; Michelle C Flynn; Graeme I Lancaster; Mark A Febbraio; Jaye Chin-Dusting; Beatriz Y Hanaoka; Ian P Wicks; Andrew J Murphy
Journal:  Eur Heart J       Date:  2018-06-14       Impact factor: 29.983

Review 10.  Toll-like receptor-mediated immune responses in intestinal macrophages; implications for mucosal immunity and autoimmune diseases.

Authors:  Zejun Zhou; Miao Ding; Lei Huang; Gary Gilkeson; Ren Lang; Wei Jiang
Journal:  Clin Immunol       Date:  2016-09-09       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.